EMA, FDA Talk Real World Evidence, Mutual Recognition, Generic Drugs
Executive Summary
US FDA and European Medicines Agency may expand sharing beyond manufacturing inspections to clinical trials and generic drug applications.
You may also be interested in...
When Will Real World Evidence Be Persuasive? FDA's Temple Offers Perspective
Postmarketing studies randomized to look at real world data sets could provide the key, Temple suggests; Amgen rep describes use of real world data to support approval of leukemia drug Blincyto.
EU, US Finally Agree On Mutual Recognition Of GMP Inspections
Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.